




## Overview

- PharmAust Limited (ASX:PAA) is a clinical stage oncology company
- Lead product Monepantel ("MPL") – seeking to repurpose from vet use (sheep drench) to anti-cancer drug (dogs & humans)
- MPL targets the mTOR pathway, which plays a major role in driving cancers and non-cancerous diseases e.g. neurodegenerative disease, diabetes and ageing disorders
- Drug re-purposing lowers both risk and cost, validated model for generating significant investor returns
- Epichem is a separate profitable business with significant growth potential as it expands new revenue streams



## Pitney Pharmaceuticals

- Lead product is MPL; a repurposed drug already approved for veterinary use
- MPL has already achieved key pre-clinical and Phase 1 clinical endpoints
- Phase 1/2 clinical data in dogs shows safety, suppression of cancer biomarkers and efficacy
- Phase 1 in humans shows safety and suppression of cancer biomarkers
- Dual clinical development strategy for use of MPL as a cancer therapeutic for vet health and humans

## Epichem

- Specialist Synthetic & Medicinal Chemistry Services
- Highly awarded WA Company founded in 2003
- 23 staff including 15 PhD's
- Record \$3.05m revenues achieved in FY17
- Key Drivers for Epichem Growth:
  - Phase 2 Lab expansion to increase capacity
  - ISO17025/34 accreditation – highest 'calibration and testing' standards, expected December 2017
  - Expansion of high margin catalogue business

## Corporate Snapshot


### Share Price Performance



### Capital Structure

As at 25 October 2017		
Current Share Price	A\$	0.051
No. of Shares Outstanding	m	157.4
<b>Market Capitalisation</b>	<b>A\$m</b>	<b>8.0</b>
Cash (as at 30-Sep-17)	A\$m	2.3
Debt (as at 30-Sep-17)	A\$m	0.5
<b>Net Cash</b>	<b>A\$m</b>	<b>(1.8)</b>
<b>Enterprise Value</b>	<b>A\$m</b>	<b>6.2</b>
Unlisted Options (12c/16c)	m	22.3
<b>Enterprise Value (fully diluted)</b>	<b>A\$m</b>	<b>4.7</b>

### Shareholder Split



### Board and Management

Name	Position
Dr. Roger Aston	Executive Chairman
Dr. Richard Hopkins	CEO
Mr. Robert Bishop	Executive Director
Dr. Wayne Best	Non-Executive Director
Mr. Sam Wright	Non-Executive Director & Company Secretary

## Monepantel (MPL)

- Drug repurposing lowers both risk and cost:
  - 70% of oncology drugs fail in clinical trials due to poor efficacy and safety
  - 10 year development phase (humans) reduced to c. 6 year development phase
- Canine trial outcomes inform Human outcomes
  - Dog cancer similar to human cancer
  - Dog trials generate more predicative and produce high quality preclinical data pack
- Pet/Canine drug market in US worth US\$10b
  - 6m dogs pa diagnosed with cancer in US vs 1.7m humans
  - Vet oncology focused on quality of life, low cost and remission
  - Vet cancer market dominated by re-purposed drugs. MPL addressing unmet need for new cancer drugs


## Patents & Agreements

- Molecule is currently used in a sheep drench application owned by Elanco
- PharmAust has a strong patent position:
  - 5 patent families across the US, Australia, China, NZ and Europe
  - Broad 'method of use' for MPL across cancer and non-cancer applications
- Developing proprietary portfolio of compounds related to MPL
- Existing option agreement with Novartis Health (subsequently acquired by Elanco) to licence PAA patents for veterinary cancer applications
- Elanco patent for use of molecule expiring in 2024

## Epichem

- Lab expansion increase to meet demand
- New accreditation (expected December 2017) providing ability to expand high margin catalogues business
- Forecast sales revenue FY18 ~\$4m

## Pipeline



## Key Contacts

For further information, interested parties should contact one of the below representatives.

**Richard Hopkins**  
CEO  
PharmAust Limited  
+61 8 6167 5205  
+61 405 656 868  
[rhopkins@pharmaust.com](mailto:rhopkins@pharmaust.com)

**Peter Balsarini**  
Director, Corporate Finance  
Argonaut Perth  
+61 8 9224 6826  
+61 407 584 770  
[pbalsarini@argonaut.com](mailto:pbalsarini@argonaut.com)

**Ian Dorrington**  
Director, Stockbroking  
Argonaut Perth  
+61 8 9224 6865  
+61 417 970 988  
[iodorrington@argonaut.com](mailto:iodorrington@argonaut.com)

## PharmAust – Future Value Catalysts



## Comparable Companies

Company	Business Model	EV
 Anatara Lifesciences Limited (ASX:ANR)	Developing Detach™, a natural, plant based product that prevents and treats diarrhea in production animals, reducing the use of antibiotics and animal deaths	A\$66.3m
 Apium Animal Health Limited (ASX:AHX)	Vertically integrated animal health business providing products and services to production and mixed animals	A\$108.2m
 AB Science S.A. (EN:AB)	Clinical stage oncology company Developing same drug for vet and human markets Extending to non-oncology indications	A\$513.8m <sup>1</sup>
 Kindred Biosciences Inc. (NASDAQ:KIN)	Development stage bio-pharmaceutical company Re-purposed biologics/small molecules for animal health	A\$236.6m <sup>2</sup>
 Oasmia Pharmaceutical AB (STO:OASM)	Bio-pharmaceutical company Develops chemotherapeutic drugs for treatment of cancer in humans and companion animals	A\$71.8m <sup>3</sup>

<sup>1</sup> As at 30 June 2017, assuming AUD/EUR \$0.65 exchange rate

<sup>2</sup> As at 30 June 2017, assuming AUD/USD \$0.79 exchange rate

<sup>3</sup> As at 31 July 2017, assuming AUD/SEK \$0.16 exchange rate

## Potential Investors Considerations

- Epichem revenues underpinning value of existing business with late stage clinical asset
- Repurposing of MPL – clinical trials confirm safety and efficacy
- Developing same molecule for multiple markets, lowers costs/risks and accelerates path to short-medium value inflection catalysts
- Existing relationship with large pharma who are in acquisition mode